MNKD
Mannkind Corp Health Care Pharmaceutical Preparations Russell 3000
$3.50Close
$1.1BMarket cap
$2.28 – $6.2152-week range
Nov 4, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 22 · weaker than 78% of stocks over 12 months
- Far from its high 44% below its 52-week high
- Earnings shrinking EPS −2970% year on year
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
44%
1wk
up 9.7%
price change
1mo
down 10.3%
price change
12-month return
down 37%
market up 11% ·
its own down 48%
F-score
4 / 9
Weak
Altman Z
-4.10
Elevated risk
P/E
183.8×
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 2.9%
EBIT / enterprise value
Cheaper than
37%
of the market · expensive
Revenue growth
up 22%
year on year
EPS growth
down 2970%
latest quarter · -2739 pts
Sales growth
up 43%
latest quarter · +28 pts
ROE
—
return on equity
Free cash margin
up 4%
$13.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
5.5×
Interest cover
—EBIT / interest
Piotroski tests
- profitability slipped from last year
- took on more long-term debt
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profits backed by cash
- assets working harder
Trade setup
ATR%
5.1%
$0.18 a day · 2×ATR $3.14
RS
22 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.69
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 1 of 8
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$51.0M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Heavily indebted Net debt is 5.5 times EBITDA — roughly 5 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Gross margin narrowing Gross margin fell from 93.9% to 92.3%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026-1% vs market2 sessions after results
Financials
- Gross 92%
- Net 2%
- Free cash 4%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $65.1M | $75.4M | $99.8M | $199.0M | $285.5M | $349.0M |
| Gross margin | 77% | 78% | 84% | 90% | 94% | 92% |
| Operating income | -$47.9M | -$47.0M | -$64.1M | $8.7M | $72.6M | $38.8M |
| Net income | -$57.2M | -$80.9M | -$87.4M | -$11.9M | $27.6M | $5.9M |
| Net margin | -88% | -107% | -88% | -6% | 10% | 2% |
| Earnings per share | -$0.26 | -$0.32 | -$0.34 | -$0.04 | $0.10 | $0.02 |
| Free cash flow | -$28.9M | -$73.2M | -$88.3M | -$8.3M | $32.8M | $13.7M |
| Free cash margin | -44% | -97% | -88% | -4% | 11% | 4% |
| Cash | $67.0M | $124.2M | $69.8M | $238.5M | $46.3M | $74.9M |
| Long-term debt | $122.2M | $281.2M | $273.5M | $268.7M | $36.1M | $354.6M |
| Shareholders' equity | -$180.4M | -$209.3M | -$250.5M | -$246.2M | -$78.8M | -$51.0M |
| Shares outstanding | 242.12m | 251.48m | 263.79m | 270.03m | 302.96m | 307.83m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 21, 2026 | Other events ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 24, 2026 | Unregistered share sale · Other events ↗ |
| Jun 2, 2026 | Other events ↗ |
| May 28, 2026 | Other events ↗ |
| May 22, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Feb 26, 2026 | Results ↗ |
| Nov 10, 2025 | Other events ↗ |
| Nov 5, 2025 | Results ↗ |
| Oct 9, 2025 | Material agreement · Acquisition or disposal · New obligation ↗ |
| Aug 27, 2025 | Material agreement ↗ |